Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC
Status:
Not yet recruiting
Trial end date:
2025-11-27
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm, single center, phase II study of cadonilimab plus
mFOLFIRINOX as conversion therapy in patients with locally advanced pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University